The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Mediates Antitumor Efficacy Through Distinct Mechanisms in Two Prostate Cancer Xenograft Models